MY-673, a colchicine binding site inhibitor (CBSI), impedes tubulin polymerization and disrupts the ERK signaling pathway, consequently modulating SMAD4 protein expression in the TGF-beta/SMAD pathway. This compound effectively reduces cell proliferation and migration while inducing apoptosis in both in vivo and in vitro settings [1].
